

ABSTRACT OF THE DISCLOSURE

Cyclooxygenase-2 promoter is incorporated into adenoviral vector to mitigate the adverse effects of adenoviral suicide gene therapy by minimizing transgene expression in the liver. The promoters disclosed herein are promising tumor-specific promoters for adenoviral vector based gene therapy of gastrointestinal and pancreatic cancers.